Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Aprea Therapeutics director Marc Duey reported new equity awards rather than market trades. He received 3,135 restricted stock units on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration under certain conditions.
Duey was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, expiring on June 16, 2036. These options vest in full on June 16, 2027, subject to continued board service and similar acceleration terms. After these awards, he directly holds 259,290 common shares. An additional 602 shares are held indirectly by his spouse, and he disclaims beneficial ownership of those securities.
Aprea Therapeutics director Rifat Pamukcu reported new equity awards and updated holdings. On June 16, 2026, he received 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, subject to his continued board service and possible acceleration under certain conditions.
He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under similar service-based conditions. Following these awards, he directly holds 8,581 common shares and 12,555 options, and indirectly holds 14,108 common shares through ZNZ Holdings LLC, where he serves as Manager Partner.
Aprea Therapeutics director Bernd R. Seizinger reported equity awards that increase his stake in the company. He received 3,135 restricted stock units granted on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, as long as he continues serving on the board. He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. After these grants, he directly holds 48,910 common shares.
Aprea Therapeutics, Inc. reported results of its 2026 annual stockholder meeting. Of 12,382,776 common shares entitled to vote, 8,268,451 shares, or approximately 66.8%, were represented, establishing a quorum.
Stockholders elected three Class I directors—Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.—to serve until the 2029 annual meeting or until successors are elected and qualified. EisnerAmper LLP was ratified as independent registered public accounting firm for fiscal year 2026.
Stockholders approved an amendment to the certificate of incorporation authorizing the board to implement a reverse stock split at a ratio between one-for-three and one-for-eight, with the exact ratio and timing left to the board’s discretion. They also approved, on a non-binding basis, executive compensation and, by advisory vote, indicated a preference for annual say-on-pay votes. An adjournment proposal related to the reverse split was also approved.
Aprea Therapeutics reports a Schedule 13G filing showing Vestal Point Capital and Ryan Wilder disclose beneficial ownership of 22,654,832 shares of Common Stock, representing 9.9% of the class.
The cover pages state the total includes 22,304,832 shares issuable upon exercise of warrants; certain warrants are subject to a 9.99% Blocker. The percentage is calculated using 11,452,452 shares outstanding as of March 16, 2026.
Aprea Therapeutics, Inc. files a prospectus supplement registering 5,503,556 shares of Common Stock for resale by selling stockholders. The supplement updates the Prospectus dated December 29, 2025 and reflects assignments of Common Warrants to Squadron Master Fund LP. The resale includes (i) 26,459 shares issued in a private placement, (ii) 2,596,564 shares underlying pre-funded warrants, (iii) 2,623,023 shares underlying common stock purchase warrants, and (iv) 257,510 shares underlying warrants issued as placement compensation. The filing states there were 12,382,776 shares outstanding as of May 13, 2026. The supplement shows, including Squadron Master Fund LP: 536,480 shares listed as being offered, with post-offering beneficial ownership reported as 1,433,878 shares (9.99%).
Aprea Therapeutics, Inc. reported a Q1 2026 net loss of $3.3 million, slightly improved from $3.9 million a year earlier, as lower research and development spending offset the end of grant revenue. Cash and cash equivalents reached $46.5 million, and management believes this will fund operations into the first quarter of 2028.
Research and development expenses fell to $1.6 million, mainly from reduced ATRN-119 monotherapy activity, while general and administrative costs were stable at about $1.8 million. Operating cash outflow was $2.8 million in the quarter.
The company strengthened its balance sheet with approximately $34.6 million in net proceeds from January and March 2026 private placements involving common stock and pre-funded warrants. Aprea continues to advance its synthetic lethality oncology pipeline, including WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119, supported by an expanded base of warrants and equity capital.
Aprea Therapeutics reported first quarter 2026 results and highlighted progress in its oncology pipeline. The company is evaluating APR-1051 in the ACESOT-1051 Phase 1 trial, where two partial responses were observed, one of which was confirmed and remains on study. A recent $30 million private placement strengthened the balance sheet and is expected to support expanded enrollment for APR-1051.
Cash and cash equivalents rose to $46.5 million as of March 31, 2026, up from $14.6 million at December 31, 2025, which the company believes will fund operations into the first quarter of 2028. Aprea posted an operating loss of $3.4 million, down from $4.1 million a year earlier, and a net loss of $3.3 million, or ($0.22) per share, versus $3.9 million, or ($0.66) per share, in the prior-year quarter.
Aprea Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, a potential reverse stock split and executive pay matters. The June 16, 2026 meeting will be held online for holders of record as of April 21, 2026.
Stockholders will vote on electing three Class I directors to 2029, ratifying EisnerAmper LLP as auditor for 2026, approving a reverse stock split at a Board-selected ratio between 1-for-3 and 1-for-8 without reducing authorized shares, and two advisory “say on pay” items. A proposal also allows adjourning the meeting to seek more proxies if needed for the reverse split.